We're Here for You!
The IMF is dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure.
I am a...
In this week’s blog, IMF Chief Scientific Officer Dr. Brian G.M. Durie delves deeper into the meaning of “cure” when it comes to multiple myeloma. He emphasizes the importance of having a clear understanding of implications that can possibly bring about this outcome and how close myeloma patients are to achieving this much-desired goal. Dr. Durie tackles the basic requirements (i.e., no active myeloma, outcome or survival based on age, gender, and co-morbidities, and very good to excellent quality of life); key questions that need to be addressed; a reality check for long-term myeloma survivors; as well as a practical definition of functional cure. While it seems that finding a cure for myeloma is like seeing a “mirage in the desert,” Dr. Durie is hopeful that it will materialize into something tangible—the cure may be seemingly elusive, but it is still achievable. READ THE BLOG.
According to a February 20, 2023 press release from Johnson & Johnson, the U.S. FDA has "approved the supplemental Biologics License Application (sBLA) for TECVAYLI® (teclistamab-cqyv) for a reduced dosing frequency of 1.5 mg/kg every two weeks (Q2W) in patients with relapsed or refractory multiple myeloma (RRMM) who have achieved and maintained a complete response (CR) or better for a minimum of six months. There is a continued unmet need for patients with multiple myeloma and this approval allows increased flexibility in dosing schedule for appropriate patients with a weight-based regimen."
"Tecvayli, which is administered subcutaneously, was the first bispecific antibody targeting B-cell maturation antigen (BCMA) on multiple myeloma cells and CD3 on T-cells to activate an immune response." Read the full press release now. LEARN MORE.
In SoCal? Register now for this in-person Regional Community Workshop at the Westin San Diego Bayview (400 W Broadway) in San Diego. The event’s speakers include IMF Vice President of Support Groups Robin Tuohy, Dr. Ah-Reum (Autumn) Jeong (University of California at San Diego — La Jolla, CA), Dr. Rahul Banerjee ((Fred Hutchinson Cancer Center — Seattle, WA), and IMF Nurse Leadership Board Member Sandra Rome, RN, MN, AOCN, CNS. These speakers will cover the topics of Myeloma 101, frontline therapy, treatment options for relapsed disease, and managing the side effects and complications of myeloma and its treatments. REGISTER NOW.
The International Myeloma Foundation (IMF) is excited to announce that the 2024 San Francisco Patient and Family Seminar will take place on April 12-13, 2024, in Foster City, CA. The seminar is FREE, but in-person seating is LIMITED.
Keynote speaker for this seminar is Thomas G. Martin, MD (UCSF, Helen Diller Family Comprehensive Cancer—San Francisco, CA). He will present on the topic of “What is the Future of Myeloma?”
Other seminar presenters include IMF Chief Medical Officer Joseph Mikhael, MD (TGen, City of Hope — Scottsdale, AZ); Ajai Chari, MD (Mount Sinai — New York, New York); Amrita Krishna, MD, FACP (City of Hope — Orange County, CA); Caitlin Costello, MD (University of California — San Diego); IMF Infoline Advisor Teresa Miceli, RN, BSN, OCN; Deborah Doss, RN, OCN (Dana-Farber Cancer Institute — Boston); Wendy Thomas RN, MSN, CHPN; and Erin Bair, Esq., Staff Attorney, Triage Cancer. Topics will include a resource review of myeloma.org, Myeloma 101, understanding your labs, shared decision-making, financial considerations in myeloma, clinical trials, symptom management, and advanced care planning. REGISTER NOW.
The International Myeloma Foundation (IMF) is excited to announce the launch of the Iceland Cycling Expedition (ICE)—a 3-day, 2-night fundraiser biking tour set to take place from August 29 - September 4, 2024, in Reykjavik and around Iceland to kick off Blood Cancer Awareness Month, which happens every September. The ICE biking tour is an inaugural signature IMF Myeloma Cures fundraiser, with the goal of highlighting IMF’S diverse and robust research portfolio.
ICE will include a team of approximately twelve participants who will be individually raising funds for the IMF'S vast Research portfolio. These IMF cyclists will embark on an unforgettable journey of adventure and purpose, as they take part in this exclusive bike tour of the breathtaking landscapes of Iceland while doing it to find a cure for myeloma.Read the full press release to learn more. LEARN MORE.
On Thursday, April 18, 2024, the International Myeloma Foundation (IMF) will hold its 15th Annual Gala for the first time in New York City! Join us at the Edison Ballroom (240 W 47th St, New York, NY 10036) at 6:00 p.m. EST for this star-studded event. Hosted by Ray Romano, the Gala Benefits the Peter Boyle Research Fund and Celebrates Groundbreaking Myeloma Research, Education, Support, and Advocacy.These initiatives support research toward prevention and a cure for myeloma, as well as promote greater health equity and access to care for all.
Launched in 2007, shortly after beloved actor Peter Boyle lost his battle with myeloma, the IMF Annual Gala continues to raise funds and awareness for groundbreaking myeloma research projects. LEARN MORE.
Need assistance in creating a fundraiser? The IMF team is here for you. Find out how you can help in the fight against myeloma today!